Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 4,321 shares of the firm’s stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $16.06, for a total value of $69,395.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Phil Skolnick also recently made the following trade(s):
- On Monday, November 5th, Phil Skolnick sold 1,821 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $18.01, for a total value of $32,796.21.
- On Thursday, October 4th, Phil Skolnick sold 4,778 shares of Opiant Pharmaceuticals stock. The stock was sold at an average price of $18.32, for a total value of $87,532.96.
Shares of NASDAQ OPNT opened at $15.93 on Friday. The company has a market capitalization of $61.35 million, a price-to-earnings ratio of 38.10 and a beta of 0.24. Opiant Pharmaceuticals Inc has a 12 month low of $12.75 and a 12 month high of $32.28.
A number of hedge funds and other institutional investors have recently modified their holdings of OPNT. Northern Trust Corp acquired a new stake in shares of Opiant Pharmaceuticals during the second quarter valued at about $350,000. Brasada Capital Management LP acquired a new stake in shares of Opiant Pharmaceuticals during the third quarter valued at about $268,000. Granite Point Capital Management L.P. acquired a new stake in shares of Opiant Pharmaceuticals during the third quarter valued at about $1,340,000. Stonepine Capital Management LLC purchased a new position in shares of Opiant Pharmaceuticals in the third quarter valued at approximately $3,320,000. Finally, Vanguard Group Inc. boosted its stake in shares of Opiant Pharmaceuticals by 25.1% in the third quarter. Vanguard Group Inc. now owns 105,432 shares of the technology company’s stock valued at $1,883,000 after purchasing an additional 21,151 shares during the period. 17.01% of the stock is currently owned by institutional investors.
Several brokerages have commented on OPNT. Cantor Fitzgerald set a $42.00 price target on Opiant Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 28th. ValuEngine raised Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 4th.
TRADEMARK VIOLATION WARNING: “Phil Skolnick Sells 4,321 Shares of Opiant Pharmaceuticals Inc (OPNT) Stock” was originally reported by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/12/08/phil-skolnick-sells-4321-shares-of-opiant-pharmaceuticals-inc-opnt-stock/3064270.html.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.